Maintaining investigator blinding in RCTs, especially when dealing with subcutaneous and intramuscular injections of investigational medicinal products (IMP), can be challenging.Discrepancies in the appearance and viscosity of active and placebo injections have posed a hurdle. Our study compared the performance of A-INJ (specifically, the Autoject 2) against conventional syringes (CS) for delivering 1 ml doses of both placebo and reference IMP.

The results demonstrated:

- No statistically significant differences in injectate delivery between A-INJ and CS.

- Investigators were largely unable to differentiate between the two solutions when using A-INJ, effectively maintaining blinding.

This suggested that A-INJ systems offer a promising solution for RCTs, eliminating the need to modify placebos with additives or colorants, or to utilise costly unblinded staff. These findings add to the growing body of evidence highlighting the advantages of A-INJs in administering injectable compounds during RCTs, opening up new possibilities for their utility in clinical research.

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more


AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event